A novel AI-based score for assessing the prognostic value of intra-epithelial lymphocytes in oral epithelial dysplasia.
Autor: | Shephard AJ; Tissue Image Analytics Centre, Department of Computer Science, University of Warwick, Coventry, UK., Mahmood H; School of Clinical Dentistry, University of Sheffield, Sheffield, UK., Raza SEA; Tissue Image Analytics Centre, Department of Computer Science, University of Warwick, Coventry, UK., Khurram SA; School of Clinical Dentistry, University of Sheffield, Sheffield, UK., Rajpoot NM; Tissue Image Analytics Centre, Department of Computer Science, University of Warwick, Coventry, UK. n.m.rajpoot@warwick.ac.uk. |
---|---|
Jazyk: | angličtina |
Zdroj: | British journal of cancer [Br J Cancer] 2024 Nov 30. Date of Electronic Publication: 2024 Nov 30. |
DOI: | 10.1038/s41416-024-02916-z |
Abstrakt: | Background: Oral epithelial dysplasia (OED) poses a significant clinical challenge due to its potential for malignant transformation and the lack of reliable prognostic markers. Current OED grading systems do not reliably predict transformation and suffer from considerable observer variability. Recent studies have highlighted that peri-epithelial lymphocytes may play an important role in OED malignant transformation, with indication that intra-epithelial lymphocytes (IELs) may also be important. Methods: We propose a novel artificial intelligence (AI) based IEL score from Haematoxylin and Eosin (H&E) stained Whole Slide Images (WSIs) of OED tissue slides. We determine the prognostic value of our IEL score on a digital dataset of 219 OED WSIs (acquired using three different scanners), compared to pathologist-led clinical grading. Results: Our IEL scores demonstrated significant prognostic value (C-index = 0.67, p < 0.001) and were shown to improve both the binary/WHO grading systems in multivariate analyses (p < 0.001). Nuclear analyses confirmed the positive association between higher IEL scores, more severe OED and malignant transformation (p < 0.05). Conclusions: This underscores the potential importance of IELs, and by extension our IEL score, as prognostic indicators in OED. Further validation through prospective multi-centric studies is warranted to confirm the clinical utility of IELs. Competing Interests: Competing interests: NMR is the co-founder, CEO and CSO of Histofy Ltd., UK. He is also the GSK Chair of Computational Pathology and is in receipt of research funding from GSK and AstraZeneca. SAK is a shareholder of Histofy Ltd. All other authors have no competing interests to declare. Ethics approval and consent to participate: Ethical approval was obtained by the NHS Health Research Authority West Midlands (18/WM/0335) and experiments were conducted in compliance with the Declaration of Helsinki. Written consent was not required as data was collected from surplus archived tissue. Data collected were fully anonymised. (© 2024. The Author(s).) |
Databáze: | MEDLINE |
Externí odkaz: |